The stream · Daily digest
The stream: Tuesday, October 27, 2026
11 briefs from ClinicalTrials.gov and the Federal Register, grouped by desk. Each is two sentences from one primary source, linked to it.
Machine-summarized from primary sources; not independently reported. How we use automation
Clinical trials · 8
-
Izalontamab brengitecan versus platinum chemotherapy in EGFR-mutated NSCLC
In a phase 3 trial in China, 432 participants with EGFR-mutated advanced non-squamous NSCLC received either izalontamab brengitecan or platinum-based chemotherapy. Median BICR-assessed progression-free survival was 11·1 months with izalontamab brengitecan versus 5·7 months with chemotherapy (HR 0·40, 95% CI 0·31-0·51).
Source: PubMed record of a Phase III journal article, October 26, 2026
-
Rudin et al. Report extended follow-up of tarlatamab in SCLC
The authors reported that median overall survival was 13.6 months with tarlatamab versus 8.4 months with chemotherapy, with 12-month OS rates of 55.9% versus 39.0%. Grade ≥3 treatment-related adverse events decreased over time, with no serious events after 12 months.
Source: PubMed record of a Phase III journal article, October 26, 2026
-
AbbVie submits BLA for etentamig to FDA for relapsed/refractory multiple myeloma
AbbVie announced the submission of a Biologics License Application for etentamig, a second-generation BCMA x CD3 bispecific antibody, to the U.S. FDA for adults with relapsed or refractory multiple myeloma. The company cited Phase 3 CERVINO study results showing a 74.0% overall response rate versus 45.7% for investigator's choice and a 60% risk reduction in progression-free survival.
Source: Company press release (PR Newswire), October 27, 2026
-
Hanmi registers Phase 3 trial of HIP2602 in erectile dysfunction
The study, led by Hanmi Pharmaceutical Company Limited, plans to enroll 225 participants and begin in October 2026. It is a multicenter, randomized, double-blind Phase III trial evaluating the efficacy and safety of HIP2602 in erectile dysfunction patients.
Source: ClinicalTrials.gov registry record, October 27, 2026
-
AbbVie registers Phase 3 trial of upadacitinib in pediatric non-segmental vitiligo
The study will enroll approximately 154 participants aged 6 to <12 years and is expected to start on January 28, 2027. It is to evaluate the efficacy, safety, and tolerability of upadacitinib over 48 weeks of treatment followed by 112 weeks of continued blinded therapy.
Source: ClinicalTrials.gov registry record, October 27, 2026
-
Swedish Orphan Biovitrum registers Phase 3 trial of pegcetacoplan in kidney transplant recipients
The study, titled PRESERVE, plans to enroll 30 participants and has a planned start date of January 21, 2027. It aims to assess the efficacy and safety of pegcetacoplan for preventing recurrent C3G or primary IC-MPGN, with a planned primary completion date of January 17, 2031.
Source: ClinicalTrials.gov registry record, October 27, 2026
-
Amneal Pharmaceuticals registers Phase 3 trial of testosterone cypionate auto-injector
The Phase 3 study, recruiting 190 participants, was first posted on ClinicalTrials.gov on October 27, 2026, with primary completion projected for March 31, 2027. It aims to evaluate the safety, efficacy, and usability of a weekly subcutaneous testosterone cypionate auto-injector in adult males with hypogonadism.
Source: ClinicalTrials.gov registry record, October 27, 2026
-
Bayer posts results of Phase 3 finerenone trial in CKD with type 1 diabetes
The study, completed with 242 participants, compared finerenone plus standard of care to placebo in people with chronic kidney disease and type 1 diabetes. Results were first posted on ClinicalTrials.gov on October 27, 2026.
Source: ClinicalTrials.gov results record, October 27, 2026
Regulation · 2
-
FDA releases draft guidance on U.S.-origin statements for seafood labeling
The notice was published on October 27, 2026. It will provide examples of labeling statements that the FDA would consider truthful and not misleading once finalized.
Source: Federal Register notice, October 27, 2026
-
FDA determines PEPCID RPD famotidine tablets not withdrawn for safety or effectiveness
The agency decided that the 20 mg and 40 mg orally disintegrating tablets were not removed from sale. This determination will allow FDA to approve abbreviated new drug applications for these products if all other legal and regulatory requirements are met.
Source: Federal Register notice, October 27, 2026
Policy · 1
-
Patrik Jonsson retires after 36 years; Ilya Yuffa named Lilly Global Markets president
Patrik Jonsson has decided to retire at the end of 2026 after a 36-year career at Lilly. Ilya Yuffa will become executive vice president and president of Lilly Global Markets on Jan. 1, 2027, overseeing customer strategy worldwide.
Source: Company press release (PR Newswire), October 27, 2026